AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29866385 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-assisted treatment (MAT) with extended-release injectable naltrexone (XR-NTX) for alcohol use disorder or buprenorphine/naloxone (BUP/NX) for opioid use disorder
Number of subjects: 392
Study 29866385 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (CC) intervention
Number of subjects: 392
Study 29866385 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving at least one session of BT
Number of subjects: 392
Study 29866385 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-stigma
Number of subjects: 392
Study 29866385 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 392
Study 29866385 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 392
Study 29866385 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of heroin abuse or dependence
Number of subjects: 392
Study 29866385 — intervention group
Group type: EXPERIMENTAL
Intervention: Being homeless
Number of subjects: 392
Study 29866385 — intervention group
Group type: EXPERIMENTAL
Intervention: Being of 'other' or 'multiple' races compared to being White
Number of subjects: 392
Study 29866385 — intervention group
Group type: EXPERIMENTAL
Intervention: Having been arrested within 90 days of baseline
Number of subjects: 392
Study 26673981 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (n = 11)
Number of subjects: 43
Study 26673981 — intervention group
Group type: COMPARATOR
Intervention: Second dose of IVIG (n = 32)
Number of subjects: 43
Study 26673981 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery outcomes and adverse events
Number of subjects: 43
Study 25671931 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone (75 mg/kg in three divided doses orally)
Number of subjects: 134
Study 25671931 — intervention group
Group type: COMPARATOR
Intervention: Deferrioxamine (50 mg/kg/24hrs for 5 days/week as parental infusion)
Number of subjects: 134
Study 21755329 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI after six adjuvant TMZ courses
Number of subjects: 46
Study 21755329 — intervention group
Group type: EXPERIMENTAL
Intervention: (201)Tl SPECT after three adjuvant TMZ courses
Number of subjects: 46
Study 21755329 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MRI in recurrent glioma patients
Number of subjects: 46
Study 21755329 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up MRIs during TMZ in recurrent glioma patients
Number of subjects: 46
Study 21755329 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline (201)Tl SPECT in recurrent glioma patients
Number of subjects: 46
Study 19384263 — intervention group
Group type: EXPERIMENTAL
Intervention: MeNZB vaccine (25 mug) administered with routine immunizations and a fourth dose at 10 months (n = 250)
Number of subjects: 375
Study 19384263 — intervention group
Group type: COMPARATOR
Intervention: Routine immunizations only (Group 2, n = 125)
Number of subjects: 375
Study 17569575 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer reminders for antibiotic prescriptions
Number of subjects: 53
Study 17569575 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer reminders for asthma/COPD prescriptions
Number of subjects: 53
Study 17569575 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific recommendations (quinolones for cystitis, corticosteroids for COPD, antibiotics for acute sore throat)
Number of subjects: 53
Study 15222528 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine
Number of subjects: 31
Study 15222528 — intervention group
Group type: EXPERIMENTAL
Intervention: fexofenadine
Number of subjects: 31
Study 15222528 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine
Number of subjects: 31
Study 15222528 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study 12081584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 200
Study 12081584 — intervention group
Group type: COMPARATOR
Intervention: Calcium-based phosphate binders
Number of subjects: 200
Study 9764988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (10 mg kg(‐1).d(‐1), given in single daily doses)
Number of subjects: 48
Study 9764988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (10 mg kg(‐1).d(‐1), given in multiple daily doses)
Number of subjects: 48
Study 9764988 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 9764988 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 48
Study 7932289 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-psychotic unipolar depression and alcoholism (39 families)
Number of subjects: 372
Study 7932289 — intervention group
Group type: COMPARATOR
Intervention: Non-psychotic unipolar depression without alcoholism (160 families)
Number of subjects: 372
Study 7932289 — intervention group
Group type: COMPARATOR
Intervention: Alcoholism without psychotic or major affective disorders (64 families)
Number of subjects: 372
Study 7932289 — intervention group
Group type: COMPARATOR
Intervention: General population (109 families)
Number of subjects: 372
Study 3265347 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose perioperative interferon-alpha (r-HuIFN alpha), 2 megaunits daily for 1 week starting the evening before surgery
Number of subjects: 30
Study 3265347 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 31994003 — intervention group
Group type: EXPERIMENTAL
Intervention: Group embryo culture under low‐oxygen tension in benchtop incubators
Number of subjects: 148
Study 31994003 — intervention group
Group type: COMPARATOR
Intervention: Control culture strategy (individual culture under atmospheric oxygen tension in large‐box incubators)
Number of subjects: 148
Study 29473352 — intervention group
Group type: EXPERIMENTAL
Intervention: Pricking and cupping combined with rehabilitation training
Number of subjects: 60
Study 29473352 — intervention group
Group type: COMPARATOR
Intervention: Western medication (Baclofen 10 mg, 3 times a day for 4 weeks)
Number of subjects: 60
Study 27261998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic herbal compound preparation (Murraya koenigii, Punica granatum, Curcuma longa), administered as a decoction twice daily for 4 weeks
Number of subjects: 32
Study 27261998 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered as ground powders for 4 weeks
Number of subjects: 32
Study 27261998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic herbal compound preparation
Number of subjects: 32
Study 27261998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 25764956 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-containing hydrofiber (SCH) dressing (Aquacel Ag)
Number of subjects: 40
Study 25764956 — intervention group
Group type: EXPERIMENTAL
Intervention: Microorganism-binding (MB) dressing (Cutimed Sorbact)
Number of subjects: 40
Study 23030822 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel-sealing device (VSD)
Number of subjects: 120
Study 23030822 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (group 1)
Number of subjects: 120
Study 21114863 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice‐based intervention to assess and manage unmet needs of caregivers.
Number of subjects: 520
Study 21114863 — intervention group
Group type: COMPARATOR
Intervention: Usual care for caregivers.
Number of subjects: 520
Study 17928573 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone augmentation (0.25-1 mg)
Number of subjects: 93
Study 17928573 — intervention group
Group type: COMPARATOR
Intervention: Placebo augmentation
Number of subjects: 93
Study 16299352 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT emulsion (1:1)
Number of subjects: 12
Study 16299352 — intervention group
Group type: COMPARATOR
Intervention: LCT emulsion
Number of subjects: 12
Study 12571482 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture ratio of local bone to AWGC granules 2:1
Number of subjects: 35
Study 12571482 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture ratio of local bone to AWGC granules 1:1
Number of subjects: 35
Study 12571482 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture ratio of local bone to AWGC granules 1:2
Number of subjects: 35
Study 10998025 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal beclomethasone (400 microgram/day)
Number of subjects: 19
Study 10998025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8838964 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral amoxicillin 0.75 g 3 times daily (n = 50)
Number of subjects: 106
Study 8838964 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 56)
Number of subjects: 106
Study 1627419 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified radical mastectomy or partial mastectomy plus radiation therapy
Number of subjects: 465
Study 1627419 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 465
Study 6476838 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone at dosages of 2 to 4 mg/m2 with a 5‐day schedule or 6 to 12 mg/m2 with a one day schedule, repeating at 4‐week intervals
Number of subjects: 33
Study 6476838 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 33
Study 31206579 — intervention group
Group type: EXPERIMENTAL
Intervention: Vida PURA intervention (personalized feedback, motivational interviewing, referral to services)
Number of subjects: 121
Study 31206579 — intervention group
Group type: COMPARATOR
Intervention: Control group (information about local substance use treatment services)
Number of subjects: 121
Study 29677524 — intervention group
Group type: EXPERIMENTAL
Intervention: Community based Depression Intervention Programme (ComDIP)
Number of subjects: 60
Study 29677524 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 60
Study 26945358 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% human albumin (HA)
Number of subjects: 40
Study 26945358 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer solution (LR)
Number of subjects: 40
Study 25091093 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital atherectomy plus balloon angioplasty (OA + BA)
Number of subjects: 50
Study 25091093 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty alone (BA)
Number of subjects: 50
Study 21052672 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroRNA profiles in patients with systemic scleroderma (SSc)
Number of subjects: 6
Study 21052672 — intervention group
Group type: COMPARATOR
Intervention: Healthy control individuals
Number of subjects: 6
Study 19155234 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS-driven therapy (group A)
Number of subjects: 435
Study 19155234 — intervention group
Group type: COMPARATOR
Intervention: Routine care (group B)
Number of subjects: 435
Study 17698144 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antimicrobial scrub with 4% chlorhexidine
Number of subjects: 100
Study 17698144 — intervention group
Group type: COMPARATOR
Intervention: Normal hygiene (soap and water)
Number of subjects: 100
Study 16361166 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (0.75% 6 mg, diluted to 2 ml with distilled water)
Number of subjects: 60
Study 16361166 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 60
Study 16361166 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine and Levobupivacaine
Number of subjects: 60
Study 12099982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (dosage not specified)
Number of subjects: 22
Study 10641952 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625mg of conjugated equine estrogens plus 2.5mg of medroxyprogesterone daily (Prempro)
Number of subjects: 2763
Study 10641952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763
Study 7772614 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 7772614 — intervention group
Group type: EXPERIMENTAL
Intervention: MAOIs
Number of subjects: 0
Study 7772614 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective MAO-A inhibitors (moclobemide, brofaromine)
Number of subjects: 0
Study 7772614 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine (double-blind placebo-controlled study)
Number of subjects: 0
Study 7772614 — intervention group
Group type: EXPERIMENTAL
Intervention: MSH/ACTH analog Org 2766
Number of subjects: 0
Study 2304788 — intervention group
Group type: EXPERIMENTAL
Intervention: Child alone with no parent participation
Number of subjects: 36
Study 2304788 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother and child treated in the same session
Number of subjects: 36
Study 2304788 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother and child treated in separate but concurrent session
Number of subjects: 36
Study 2304788 — intervention group
Group type: COMPARATOR
Intervention: N/A (control group not explicitly defined)
Number of subjects: 36
Study 2304788 — intervention group
Group type: EXPERIMENTAL
Intervention: N/A (secondary analysis)
Number of subjects: 36
Study 7388537 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk consumption
Number of subjects: 0
Study 7388537 — intervention group
Group type: COMPARATOR
Intervention: Iron supplementation
Number of subjects: 0
Study 7388537 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk of Zebu cattle
Number of subjects: 0
Study 31865631 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised action plan including the COPD Assessment Test (CAT)
Number of subjects: 75
Study 31865631 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75
Study 30981585 — intervention group
Group type: EXPERIMENTAL
Intervention: Second generation antipsychotics (SGAs) - haloperidol, flupentixol
Number of subjects: 136
Study 30981585 — intervention group
Group type: COMPARATOR
Intervention: First generation antipsychotics (FGAs) - aripiprazole, olanzapine, quetiapine
Number of subjects: 136
Study 28834469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood-pressure control (target, <120 mm Hg)
Number of subjects: 0
Study 28834469 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood-pressure control (target, <140 mm Hg)
Number of subjects: 0
Study 28834469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood-pressure control
Number of subjects: 0
Study 25689936 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 7.5 mg
Number of subjects: 0
Study 25689936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23513277 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-Hz stroboscopic illumination
Number of subjects: 18
Study 23513277 — intervention group
Group type: COMPARATOR
Intervention: nonstroboscopic condition
Number of subjects: 18
Study 21534834 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of target behavior (choice condition)
Number of subjects: 60
Study 21534834 — intervention group
Group type: COMPARATOR
Intervention: No choice of target behavior (assigned condition)
Number of subjects: 60
Study 21534834 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management skills training
Number of subjects: 60
Study 21534834 — intervention group
Group type: COMPARATOR
Intervention: No self-management skills training
Number of subjects: 60
Study 18794865 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide and G-CSF
Number of subjects: 55
Study 18794865 — intervention group
Group type: COMPARATOR
Intervention: Etoposide, G-CSF and rituximab
Number of subjects: 55
Study 16931805 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic instructions for missed pill guidance
Number of subjects: 864
Study 16931805 — intervention group
Group type: COMPARATOR
Intervention: Text-only instructions for missed pill guidance
Number of subjects: 864
Study 16931805 — intervention group
Group type: COMPARATOR
Intervention: Complex instructions (both 21- and 28-day versions)
Number of subjects: 864
Study 16931805 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified instructions
Number of subjects: 864
Study 15207943 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-4 (20 microg)
Number of subjects: 7
Study 15207943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 11026992 — intervention group
Group type: EXPERIMENTAL
Intervention: Local contrast enhancement
Number of subjects: 12
Study 11026992 — intervention group
Group type: EXPERIMENTAL
Intervention: Histogram equalization
Number of subjects: 12
Study 11026992 — intervention group
Group type: COMPARATOR
Intervention: Control images
Number of subjects: 12
Study 9460867 — intervention group
Group type: EXPERIMENTAL
Intervention: Russian vaccine 'Combiotech'
Number of subjects: 0
Study 9460867 — intervention group
Group type: EXPERIMENTAL
Intervention: American vaccine 'H-B-Vax II'
Number of subjects: 0
Study 9460867 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines (schedule 0-1-2 months)
Number of subjects: 0
Study 9460867 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines (schedule 0-1-6 months)
Number of subjects: 0
Study 9460867 — intervention group
Group type: COMPARATOR
Intervention: Children receiving only the vaccines
Number of subjects: 0
Study 8404168 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline (TE)
Number of subjects: 14
Study 8404168 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide (IB)
Number of subjects: 14
Study 2877596 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (100 micrograms/kg)
Number of subjects: 12
Study 2877596 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium (100 micrograms/kg)
Number of subjects: 12
Study 2877596 — intervention group
Group type: COMPARATOR
Intervention: Comparison of vecuronium and pancuronium
Number of subjects: 12
Study 30776537 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong opioids
Number of subjects: 498
Study 30776537 — intervention group
Group type: COMPARATOR
Intervention: Previous weak opioid therapy
Number of subjects: 498
Study 30776537 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 498
Study 30384498 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team management (multidisciplinary assessments and individual rehabilitation management)
Number of subjects: 427
Study 30384498 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT)
Number of subjects: 427
Study 30384498 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 427
Study 26749026 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2%
Number of subjects: 76
Study 26749026 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 76
Study 25243960 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzhenghuayu capsule
Number of subjects: 181
Study 25243960 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzhenghuayu capsule plus propranolol
Number of subjects: 181
Study 25243960 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 181
Study 25243960 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzhenghuayu capsule alone
Number of subjects: 181
Study 25243960 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 181
Study 22983753 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-responsive interventions targeting adults and/or children to promote healthy behaviors
Number of subjects: 0
Study 22983753 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19841149 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 41
Study 19841149 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (AQ-AS)
Number of subjects: 41
Study 17134723 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral movement training
Number of subjects: 12
Study 17134723 — intervention group
Group type: COMPARATOR
Intervention: Unilateral movement training
Number of subjects: 12
Study 16359410 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 98
Study 16359410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 11963783 — intervention group
Group type: EXPERIMENTAL
Intervention: New perforated PDS foil (0.15 mm thickness)
Number of subjects: 0
Study 11963783 — intervention group
Group type: COMPARATOR
Intervention: Titanium dynamic mesh (0.3 mm thickness)
Number of subjects: 0
Study 9797054 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate, sodium fluoride, cetylpyridinium chloride mouthrinse
Number of subjects: 90
Study 9797054 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 90
Study 9797054 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 90
Study 7640497 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound salviae miltiorrhizae injection
Number of subjects: 41
Study 7640497 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 2486590 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine + 1 mg butorphanol (Group I)
Number of subjects: 40
Study 2486590 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine + 2 mg butorphanol (Group II)
Number of subjects: 40
Study 2486590 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine + 2 mg morphine (Group III)
Number of subjects: 40
Study 2486590 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine alone (Group IV)
Number of subjects: 40
Study 779383 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth I gastric resection
Number of subjects: 45
Study 779383 — intervention group
Group type: COMPARATOR
Intervention: Truncal vagotomy and pyloroplasty
Number of subjects: 45
Study 31369680 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal muscle thickness (TMT) above the cutoff of 7.2 mm
Number of subjects: 596
Study 28109962 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation strategies (three different strategies)
Number of subjects: 1341
Study 28109962 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurvivors (higher levels of Ang-2 and sFLT-1, and lower levels of VEGF)
Number of subjects: 1341
Study 28109962 — intervention group
Group type: EXPERIMENTAL
Intervention: sFLT-1
Number of subjects: 1341